PRIMA Retinal Implant Sustained Vision Gains
A long-term study has shown that the PRIMA device successfully preserves and improves central vision in patients with retinal atrophy.
Updated on Oct. 11, 2026 in Biotech
Live Poll
Would you consider a retinal implant to restore vision despite the risk of surgical complications?
The PRIMA retinal implant system demonstrated sustained visual improvement over a 36-month follow-up period in the PRIMAvera trial. The device has already received regulatory approval for use in Europe as of July 2026.
Why it matters
This technology restores central vision by replacing lost photoreceptor functions, offering a potential solution for patients suffering from retinal atrophy. The results suggest the implant can provide stable, long-term assistance for everyday tasks.
The system utilizes glasses to convert visual data into near-infrared light, which the implant then transforms into electrical current to stimulate retinal bipolar and ganglion cells. Participants saw an average visual acuity improvement of -0.59 logMAR.
The players
Science Corporation
This biotechnology firm is responsible for developing the PRIMA retinal implant and currently plans to seek FDA approval.
PRIMAvera trial
This clinical study evaluated the efficacy and safety of the PRIMA retinal implant in 38 patients over a 36-month duration.
The details
During the 36-month study, over 80% of patients reported the ability to read letters and words at the 12-month mark. By the end of the trial, participants were able to perform advanced tasks, while untreated control eyes experienced measurable vision loss.
Timeline
The PRIMA device received formal approval in Europe in July 2026.
Patients were evaluated for reading ability at the 12-month interval.
Advanced task performance was measured between 24 and 36 months.
The final study follow-up period concluded at 36 months.
The Tech Race
This development represents a major shift from traditional biological treatments toward hardware-based retinal restoration. It directly challenges existing limitations in treating retinal atrophy by using advanced optics to bypass damaged photoreceptors.
The device enables patients with retinal atrophy to perform previously impossible tasks like reading small text and recognizing numbers. While the implant restores a level of central vision, users must navigate the reality of potential adverse events reported during the clinical trial.
The takeaway
This study confirms that hardware-based retinal implants can successfully restore central vision for patients with degenerative conditions. Moving forward, potential candidates should consult with specialists regarding the clinical safety data and regulatory status of the device.
Further reading
Learn more about the latest innovations in Biotech.
Live Poll
Would you consider a retinal implant to restore vision despite the risk of surgical complications?
